- Shares of Idenix Pharmaceuticals (IDIX +32.8%) are on-the-move this morning, trading sharply higher on heavy volume.
- Although there are no readily apparent catalysts for the move, the company did give an HCV pipeline update Wednesday along with its Q3 report.
- Summary: Enrollment initiated for IDX21437 Phase 1/2, enrollment complete in HELIX-1 (that's the samatasvir/ simeprevir/ ribavirin GT1b and GT4 trial) with SVR4 data expected in Q4.
- Also of note, IDIX said its cash "will be sufficient to sustain its operations through December 2014." (PR)
at CNBC.com (Aug 25, 2014)